Navigation Links
Vical Names Andrew de Guttadauro Vice President, Corporate Development
Date:8/20/2007

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the enhancement of its management team with the appointment of Andrew R. de Guttadauro as Vice President, Corporate Development.

Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen Idec since February 2007, following a two-year assignment overseeing the commercial development of that company's Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, where he directed marketing efforts for the FluMist inhaled influenza vaccine. Mr. de Guttadauro served in various marketing positions of increasing responsibility at Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel, Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap Pharmaceuticals, where he served in a series of sales and marketing positions, including contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor of science degree in engineering from the United States Military Academy at West Point, followed by a three-year tour of duty as a Captain in the U.S. Army.

Vijay B. Samant, Vical's President and Chief Executive Officer, said, "We are very pleased to welcome Andrew to Vical's management team at this exciting time in the company's development. His proven leadership capabilities, solid project management skills, and breadth of experience in product sales and marketing, add another dimension to our current capabilities. As we advance with our independent product development programs, we look forward to applying Andrew's expertise in p
'/>"/>

SOURCE Vical Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... as well as changes to Martine Rothblatt , ... United Therapeutics announced the promotion of ... Executive Officer and David Zaccardelli , Pharm.D. to ... with these promotions, Dr. Rothblatt,s title will change from ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 METTLER ... inline PVM tool, ParticleView V19 with PVM ... situ probe-based particle vision and measurement tool continuously ... process conditions. ParticleView V19 then automatically prepares a ... tracking particle size and concentration changes. This compelling ...
(Date:12/15/2014)... , Dec. 15, 2014 Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology,  ... and collaborators of its exVive3D TM Human ... available in full commercial release on November 18, ... resulting in several awards for innovation. ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... Nov. 5, 2009 Complete Genomics, a third-generation ... report in the journal Science describing its ... from three complete human genomes. The consumables cost for ... nanoarrays ranged from $8,005 for 87x coverage to $1,726 ...
... , QUINCY, Mass., Nov. 6 Myriant Technologies ... of renewable bio-chemicals, Uhde Corporation of America ... of the world,s leading engineering contractors (jointly "Uhde"), ... construction (EPC) of Myriant,s biobased Succinic Acid plants ...
... Therapeutics, Inc. delivered two presentations today on its ITCA ... treatment of type 2 diabetes at the Ninth Annual ... http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) , Continuous Subcutaneous Delivery ... and Reduces Weight in a 28-day Phase 1b Study ...
Cached Biology Technology:Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... 2011 Thanks to almost $1 million in new funding ... the University of Houston (UH) will soon be enhancing its ... applied toward the purchase and installation of an advanced imaging ... With access to the latest in imaging technology, researchers from ...
... Principal investigator Dacheng Ren, assistant professor in the ... Syracuse University,s L.C. Smith College of Engineering and ... Biomaterials Institute (SBI); and co-PIs professors Rebecca Bader ... R. "Suresh" Sureshkumar (BMCE) and Ramesh Raina (biology), ...
... Fuel made from wood could become a competitive commercial ... the wood biofuel industry is supported, according to a ... is currently blended with gasoline to satisfy government-mandated targets ... corn, wood-based biofuel is considered more sustainable but is ...
Cached Biology News:UH receives $990K grant to enhance cancer research facilities 2Syracuse University receives $2 million from NSF 2Syracuse University receives $2 million from NSF 3Wood biofuel could be a competitive industry by 2020: UBC study 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... The gold standard for automated bioresearch: ... bioanalytical applications • Based on decades ... Automated accessories designed for bioresearch • ... • Versatility, reliability and ease-of-use • ...
... a single-channel sample processing head, an 8-channel ... dispenser all in one compact, affordable product. ... tips, the Precision XS autoclavable and organic ... for transferring larger volumes. Intuitive Precision Power ...
... The gold standard for automated bioresearch: ... bioanalytical applications • Based on decades ... Automated accessories designed for bioresearch • ... • Versatility, reliability and ease-of-use • ...
Biology Products: